40 ESTATE LN READING, MA 01867 Get Directions
40 ESTATE LN READING, MA 01867 Get Directions
Frontiera Therapeutics is a privately-held company, established in 2012, focused on treatments for fluid leakage from blood vessels (vascular leak) - the underlying cause of multiple serious, often fatal, conditions. The first drug under development is a unique enzyme activator that strengthens the permeability barrier and blocks vascular leak.
The first product application of Frontiera's barrier augmentation technology is a truly transformational approach to a treatment for Acute Respiratory Distress syndrome (ARDS) a devastating, often fatal condition characterized by vascular leak. ARDS is a common complication of more than 60 medical conditions, including pneumonia, sepsis, aspiration, trauma, acute mountain sickness and burns. In the US, it is fatal for approximately 40% of diagnosed patients. The current standard treatment is limited to supportive care as there are no effective drug therapy options. Frontiera is developing an innovative therapeutic that addresses the root cause of this devastating medical syndrome.
© Dun & Bradstreet, Inc. 2025. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.